(CTMX) CytomX Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 820m USD | Total Return: 76.5% in 12m
Avg Turnover: 10.9M
Qual. Beats: 0
Rev. Trend: -27.0%
Qual. Beats: 0
Warnings
Share dilution 103.4% YoY
High Debt while negative Cash Flow
Altman Z'' -15.00 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
CytomX Therapeutics (CTMX) is a clinical-stage biopharmaceutical company focused on oncology through its proprietary Probody platform. This technology utilizes conditional activation to ensure biologics are triggered specifically within the tumor microenvironment, aiming to reduce systemic toxicity and expand the therapeutic window for potent drug classes. The companys pipeline includes antibody-drug conjugates (ADCs), T-cell engagers (TCEs), and immune modulators.
The business model relies heavily on strategic partnerships with major pharmaceutical firms, including Amgen, Bristol Myers Squibb, and Moderna, to fund and co-develop its asset portfolio. In the biotechnology sector, this collaborative approach is common for platform-based companies to mitigate the high R&D costs and clinical risks associated with novel drug development. CytomX currently manages several active programs, such as CX-904 for EGFR-positive tumors and CX-2051 for EpCAM-expressing cancers.
For a deeper look into the companys valuation metrics and financial health, investors may find ValueRay to be a useful resource. CytomX continues to leverage its technology to address solid tumors that have historically been difficult to treat with traditional antibody therapies due to off-target effects on healthy tissue.
- Clinical data readouts for EGFR-CD3 bispecific CX-904 drive valuation volatility
- Strategic partnership milestones and royalty payments from BMS and Astellas sustain liquidity
- Probody platform validation determines long-term licensing potential and R&D scalability
- Regulatory approval timelines for ADC candidates CX-2051 and CX-801 impact market capitalization
- Cash runway and funding requirements dictate near-term stock performance and dilution risk
| Net Income: -59.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA 60.47 > 1.0 |
| NWC/Revenue: 897.7% < 20% (prev 24.69%; Δ 873.0% < -1%) |
| CFO/TA -0.22 > 3% & CFO -80.1m > Net Income -59.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (177.3m) vs 12m ago 103.4% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 15.53% > 50% (prev 149.8%; Δ -134.3% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.89 (Total Current Assets 353.1m - Total Current Liabilities 34.0m) / Total Assets 359.4m |
| B: -2.03 (Retained Earnings -730.2m / Total Assets 359.4m) |
| C: -0.28 (EBIT TTM -63.1m / Avg Total Assets 228.9m) |
| D: -18.52 (Book Value of Equity -730.1m / Total Liabilities 39.4m) |
| Altman-Z'' = -22.10 = D |
| DSRI: 1.37 (Receivables 646k/1.96m, Revenue 35.5m/147.6m) |
| GMI: 1.00 (GM 99.29% / 99.41%) |
| AQI: 0.31 (AQ_t 0.01 / AQ_t-1 0.03) |
| SGI: 0.24 (Revenue 35.5m / 147.6m) |
| TATA: 0.06 (NI -59.1m - CFO -80.1m) / TA 359.4m) |
| Beneish M = -3.61 (Cap -4..+1) = AAA |
As of May 24, 2026, the stock is trading at USD 3.76 with a total of 1,572,504 shares traded.
Over the past week, the price has changed by +4.16%,
over one month by -18.44%,
over three months by -32.62% and
over the past year by +76.53%.
CytomX Therapeutics has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy CTMX.
- StrongBuy: 2
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12.3 | 227.1% |
P/S = 23.0615
P/B = 2.5278
P/EG = -1.8
Revenue TTM = 35.5m USD
EBIT TTM = -63.1m USD
EBITDA TTM = -61.8m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 2.86m USD (from shortTermDebt, last quarter)
Debt = 2.86m USD (from shortLongTermDebtTotal, last quarter) (leases 2.86m already included)
Net Debt = -343.9m USD (calculated: Debt 2.86m - CCE 346.7m)
Enterprise Value = 475.8m USD (819.7m + Debt 2.86m - CCE 346.7m)
Interest Coverage Ratio = unknown (Ebit TTM -63.1m / Interest Expense TTM 0.0)
EV/FCF = -5.93x (Enterprise Value 475.8m / FCF TTM -80.2m)
FCF Yield = -16.85% (FCF TTM -80.2m / Enterprise Value 475.8m)
FCF Margin = -225.6% (FCF TTM -80.2m / Revenue TTM 35.5m)
Net Margin = -166.4% (Net Income TTM -59.1m / Revenue TTM 35.5m)
Gross Margin = unknown ((Revenue TTM 35.5m - Cost of Revenue TTM 251k) / Revenue TTM)
Tobins Q-Ratio = 1.32 (Enterprise Value 475.8m / Total Assets 359.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.86m)
Taxrate = 21.0% (US default 21%)
NOPAT = -49.8m (EBIT -63.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.38 (Total Current Assets 353.1m / Total Current Liabilities 34.0m)
Debt / Equity = 0.01 (Debt 2.86m / totalStockholderEquity, last quarter 319.9m)
Debt / EBITDA = 5.56 (negative EBITDA) (Net Debt -343.9m / EBITDA -61.8m)
Debt / FCF = 4.29 (negative FCF - burning cash) (Net Debt -343.9m / FCF TTM -80.2m)
Total Stockholder Equity = 161.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -25.83% (Net Income -59.1m / Total Assets 359.4m)
RoE = -6.63% (Net Income TTM -59.1m / Total Stockholder Equity 891.8m)
RoCE = -7.07% (EBIT -63.1m / Capital Employed (Equity 891.8m + L.T.Debt 0.0))
RoIC = -15.67% (negative operating profit) (NOPAT -49.8m / Invested Capital 318.0m)
WACC = 17.06% (E(819.7m)/V(822.5m) * Re(17.12%) + D(2.86m)/V(822.5m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 17.12% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 86.67 | Cagr: 53.79%
[DCF] Fair Price = unknown (Cash Flow -80.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.02 | # QB: 0
Revenue Correlation: -27.03 | Revenue CAGR: -11.14% | SUE: 0.48 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.10 | Chg30d=-54.41% | Revisions=-9% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.11 | Chg30d=+1.34% | Revisions=-9% | Analysts=8
EPS current Year (2026-12-31): EPS=-0.43 | Chg30d=-3.26% | Revisions=-9% | GrowthEPS=-187.1% | GrowthRev=-55.9%
EPS next Year (2027-12-31): EPS=-0.51 | Chg30d=-7.57% | Revisions=-9% | GrowthEPS=-18.2% | GrowthRev=-12.4%
[Analyst] Revisions Ratio: -9%